Literature DB >> 22144547

Long-term outcomes in hypertrophic cardiomyopathy caused by mutations in the cardiac troponin T gene.

Ferdinando Pasquale1, Petros Syrris, Juan Pablo Kaski, Jens Mogensen, William J McKenna, Perry Elliott.   

Abstract

BACKGROUND: Hypertrophic cardiomyopathy caused by mutations in the cardiac troponin T gene (TNNT2) has been associated with a high risk of sudden cardiac death (SCD) and mild left ventricular hypertrophy. However, previous studies are limited by sample size, cross-sectional design, and few data in relatives. METHODS AND
RESULTS: Five hundred fifty-two unrelated hypertrophic cardiomyopathy probands were screened for TNNT2 mutations. First-degree relatives were invited for clinical and genetic evaluation. Ninety-two individuals (20 probands and 72 relatives) carried TNNT2 mutations (51 [55%] male; 30±17 years). ECGs and echo were available in 87 (95%) and 88 (96%) individuals, respectively. ECG was normal in 13 (68%) children (<16 years) and 13 (19%) adults. Echo was normal in 18 (90%) children and 16 (24%) adults; 7 (10%) adults had a normal ECG and echo. Thirteen (65%) of 20 families had a history of SCD. Follow-up was available for 75 patients (mean, 9.9±5.2 years); 2 of 16 adults and 2 of 18 children with normal echoes developed left ventricular hypertrophy. Twenty-three (22%) received an implantable cardioverter-defibrillator (20 for primary prophylaxis). One child and 3 adults died of SCD and 2 adults were resuscitated from ventricular fibrillation. One patient had an appropriate implantable cardioverter-defibrillator discharge. The rate of cardiovascular death, transplant, and implantable cardioverter-defibrillator discharge was 1.6% (0.016 person/y; 95% confidence interval, 0.83-2.79%), and SCD 0.93% (0.0093 person/y; 95% confidence interval, 0.37-1.92%).
CONCLUSIONS: Left ventricular hypertrophy is rare in children with TNNT2 mutations. Left ventricular hypertrophy is absent in the minority of adults, but most have an abnormal ECG. Despite adverse family histories, the rate of cardiovascular death during follow-up was similar to that reported in large referral populations.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22144547     DOI: 10.1161/CIRCGENETICS.111.959973

Source DB:  PubMed          Journal:  Circ Cardiovasc Genet        ISSN: 1942-3268


  39 in total

Review 1.  Genetic testing for inherited cardiac disease.

Authors:  Arthur A M Wilde; Elijah R Behr
Journal:  Nat Rev Cardiol       Date:  2013-07-30       Impact factor: 32.419

2.  Prevalence and Progression of Late Gadolinium Enhancement in Children and Adolescents With Hypertrophic Cardiomyopathy.

Authors:  Anna Axelsson Raja; Hoshang Farhad; Anne Marie Valente; John-Paul Couce; John Lynn Jefferies; Henning Bundgaard; Kenneth Zahka; Harry Lever; Anne M Murphy; Euan Ashley; Sharlene M Day; Mark V Sherrid; Ling Shi; David A Bluemke; Charles E Canter; Steven D Colan; Carolyn Y Ho
Journal:  Circulation       Date:  2018-08-21       Impact factor: 29.690

3.  HCM-linked ∆160E cardiac troponin T mutation causes unique progressive structural and molecular ventricular remodeling in transgenic mice.

Authors:  Rachel K Moore; Lauren Tal Grinspan; Jesus Jimenez; Pia J Guinto; Briar Ertz-Berger; Jil C Tardiff
Journal:  J Mol Cell Cardiol       Date:  2013-02-19       Impact factor: 5.000

4.  The Brazilian Society of Cardiology and Brazilian Society of Exercise and Sports Medicine Updated Guidelines for Sports and Exercise Cardiology - 2019.

Authors:  Nabil Ghorayeb; Ricardo Stein; Daniel Jogaib Daher; Anderson Donelli da Silveira; Luiz Eduardo Fonteles Ritt; Daniel Fernando Pellegrino Dos Santos; Ana Paula Rennó Sierra; Artur Haddad Herdy; Claúdio Gil Soares de Araújo; Cléa Simone Sabino de Souza Colombo; Daniel Arkader Kopiler; Filipe Ferrari Ribeiro de Lacerda; José Kawazoe Lazzoli; Luciana Diniz Nagem Janot de Matos; Marcelo Bichels Leitão; Ricardo Contesini Francisco; Rodrigo Otávio Bougleux Alô; Sérgio Timerman; Tales de Carvalho; Thiago Ghorayeb Garcia
Journal:  Arq Bras Cardiol       Date:  2019-03       Impact factor: 2.000

Review 5.  Linking myofilaments to sudden cardiac death: recent advances.

Authors:  Sabine Huke
Journal:  J Physiol       Date:  2017-03-16       Impact factor: 5.182

Review 6.  Clinical outcomes associated with sarcomere mutations in hypertrophic cardiomyopathy: a meta-analysis on 7675 individuals.

Authors:  Farbod Sedaghat-Hamedani; Elham Kayvanpour; Oguz Firat Tugrul; Alan Lai; Ali Amr; Jan Haas; Tanja Proctor; Philipp Ehlermann; Katrin Jensen; Hugo A Katus; Benjamin Meder
Journal:  Clin Res Cardiol       Date:  2017-08-24       Impact factor: 5.460

7.  Allosteric effects of cardiac troponin TNT1 mutations on actomyosin binding: a novel pathogenic mechanism for hypertrophic cardiomyopathy.

Authors:  Rachel K Moore; Salwa Abdullah; Jil C Tardiff
Journal:  Arch Biochem Biophys       Date:  2014-01-28       Impact factor: 4.013

8.  Association of genome-wide variation with highly sensitive cardiac troponin-T levels in European Americans and Blacks: a meta-analysis from atherosclerosis risk in communities and cardiovascular health studies.

Authors:  Bing Yu; Maja Barbalic; Ariel Brautbar; Vijay Nambi; Ron C Hoogeveen; Weihong Tang; Thomas H Mosley; Jerome I Rotter; Christopher R deFilippi; Christopher J O'Donnell; Sekar Kathiresan; Ken Rice; Susan R Heckbert; Christie M Ballantyne; Bruce M Psaty; Eric Boerwinkle
Journal:  Circ Cardiovasc Genet       Date:  2012-12-16

9.  Delineation of Molecular Pathways Involved in Cardiomyopathies Caused by Troponin T Mutations.

Authors:  Jennifer E Gilda; Xianyin Lai; Frank A Witzmann; Aldrin V Gomes
Journal:  Mol Cell Proteomics       Date:  2016-03-28       Impact factor: 5.911

10.  Echocardiographic evaluation of pre-diagnostic development in young relatives genetically predisposed to hypertrophic cardiomyopathy.

Authors:  Morten K Jensen; Ole Havndrup; Michael Christiansen; Paal S Andersen; Anna Axelsson; Lars Køber; Henning Bundgaard
Journal:  Int J Cardiovasc Imaging       Date:  2015-08-01       Impact factor: 2.357

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.